תחזית צמיחת רווחים לשנה הבאה vandapharma.com (VNDA)

Vanda Pharmaceuticals (VNDA) possesses strong pricing power due to exclusive patents for its unique drug Hetlioz. Effective distribution through direct partners minimizes costs and ensures medication availability. The stability of mental health markets helps the company expand its patient base. The growth estimate for next year's EPS demonstrates a metric value of 71.10, which may indicate a search for strategic buyers.

This indicator assesses the expected growth rate of earnings per share, reflecting the market consensus regarding future profitability. The calculation is based on aggregated analyst forecasts for future cash flows net of operating expenses. By analyzing the projected earnings per share trend for the coming year, an investor determines the business's capitalization potential. For Vanda Pharmaceuticals (VNDA), this growth depends on the efficiency of AI molecule screening while maintaining clinical trial costs.